Loading...
XNASNXTC
Market cap22mUSD
Jan 10, Last price  
0.80USD
1D
-6.11%
1Q
-43.73%
IPO
-95.90%
Name

NextCure Inc

Chart & Performance

D1W1MN
XNAS:NXTC chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
22.63%
Rev. gr., 5y
52.18%
Revenues
0k
006,347,00022,378,000000
Net income
-63m
L-9.66%
-15,469,000-22,799,000-33,737,000-33,190,000-69,389,000-69,433,000-62,723,000
CFO
-53m
L-1.69%
-12,514,0007,992,000-35,623,000-44,954,000-57,244,000-53,886,000-52,974,000
Earnings
Mar 19, 2025

Profile

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
URL
https://www.nextcure.com/
IPO date
May 09, 2019
Employees
99
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
71,321
80,389
Unusual Expense (Income)
NOPBT
(71,321)
(80,389)
NOPBT Margin
Operating Taxes
(5,300)
Tax Rate
NOPAT
(71,321)
(75,089)
Net income
(62,723)
-9.66%
(69,433)
0.06%
Dividends
Dividend yield
Proceeds from repurchase of equity
154
66
BB yield
-0.49%
-0.17%
Debt
Debt current
656
518
Long-term debt
11,898
13,728
Deferred revenue
(1,538)
Other long-term liabilities
785
899
Net debt
(95,745)
(145,665)
Cash flow
Cash from operating activities
(52,974)
(53,886)
CAPEX
(820)
(2,116)
Cash from investing activities
39,272
67,979
Cash from financing activities
154
200
FCF
(67,839)
(76,431)
Balance
Cash
108,299
159,911
Long term investments
Excess cash
108,299
159,911
Stockholders' equity
(324,676)
(263,225)
Invested Capital
446,487
437,239
ROIC
ROCE
EV
Common stock shares outstanding
27,837
27,744
Price
1.14
-19.15%
1.41
-76.50%
Market cap
31,734
-18.88%
39,119
-76.39%
EV
(64,011)
(106,546)
EBITDA
(67,637)
(76,265)
EV/EBITDA
0.95
1.40
Interest
5,300
Interest/NOPBT